The Effects of Therapy With Teriparatide on Vascular Compliance and Osteoprotegerin/RANKL

Leland Graves III, MD

Status: Withdrawn

Conditions: Osteoporosis

Treatments: Drug: teriparatide

Study type: Interventional

Funder types: Other

Identifiers

NCT00347737

10386

Details and patient eligibility

About

The purpose of this study is to determine what effect teriparatide will have on vascular (blood vessel) compliance and osteoprotegerin (bone fluid)and RANKL levels (bone cells).

Full description

Research subjects participation is about 6 months. Subjects will give themselves daily injections of teriparatide after instruction on technique.

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Postmenopausal women and men over the age of 40 who are starting therapy with teriparatide

Exclusion criteria

• Patients with diabetes mellitus
• current smokers
• patients with a history of organ transplantation
• Patients currently of previously on glucocorticoid therapy within the past year
• Patients with serum creatinine above 1.5 mg/dl, patients with uncontrolled hypertension (BP 140/90 or greater)
• Patients ineligible for teriparatide therapy: History of metabolic bone disease other than osteoporosis
• History of radiation therapy
• Patients pregnant or nursing
• History of bone metastasis or skeletal malignancies
• History of hypercalcemia

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

1

Experimental group

Description:

Teriparatide

Treatment:

Drug: teriparatide